625 completed, 163 unknown, 150 recruiting, 138 terminated. 700 Phase 2, 359 Phase 1, 259 Phase 3, 60 Not applicable, 40 Phase 4.
Follow Cytarabine: new trials by email Literature Review of Cytarabine trials Research Report on Cytarabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-10-13 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML Unrelated Umbilical Cord Blood Infusion, Standard consolidation chemotherapy with high-dose cytarabine - AML (Acute Myelogenous Leukemia) | Phase 3 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 132 | 2026-10-01 | 2026-08-12 |
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2026-10-01 | 2026-08-27 |
| A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia Daunorubicin, Cytarabine, Liposome Mitoxantrone - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 320 | 2026-09-30 | 2026-08-26 |
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2026-09-28 | 2026-10-20 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. Sonrotoclax, cladribine, and standard-dose cytarabine - AML (Acute Myelogenous Leukemia, HSCT | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2026-09-01 | 2026-08-11 |
| Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." Revumenib, Fludarabine, Cytarabine (Ara-C) - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 24 | 2026-08-31 | 2026-07-22 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Best Practice, Biospecimen Collection, Cytarabine - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 556 | 2026-08-14 | 2026-09-04 |
| A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients Venetoclax, Azacitidine (AZA), Decitabine 20 mg/m²/day for 5 days - Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 42 | 2026-08-01 | 2026-08-19 |
| R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma Penpulimab, Rituximab, Methotrexate - Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma | Not applicable | Not yet recruiting | WEI XU | 58 | 2026-08-01 | 2026-08-14 |
| Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF) - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Not yet recruiting | Ruijin Hospital | 168 | 2026-07-30 | 2026-07-29 |
Showing 20 of 1250. Sign in to see all of them.
Leukemia, Myeloid, Acute (570) · Leukemia (282) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (235) · Lymphoma (160) · Myelodysplastic Syndromes (123) · Burkitt Lymphoma (93) · Congenital Abnormalities (89) · Lymphoma, Non-Hodgkin (86) · Leukemia, Monocytic, Acute (84) · Leukemia, Myelomonocytic, Acute (82) · Lymphoma, Large B-Cell, Diffuse (82) · Recurrence (81) · Leukemia, Erythroblastic, Acute (75) · Leukemia, Megakaryoblastic, Acute (72) · Lymphoma, Mantle-Cell (71)
M.D. Anderson Cancer Center (103) · National Cancer Institute (NCI) (87) · Children's Oncology Group (60) · St. Jude Children's Research Hospital (36) · Institute of Hematology & Blood Diseases Hospital, China (34) · Fred Hutchinson Cancer Center (28) · PETHEMA Foundation (25) · Memorial Sloan Kettering Cancer Center (23) · European Organisation for Research and Treatment of Cancer - EORTC (16) · SWOG Cancer Research Network (16) · Alliance for Clinical Trials in Oncology (15) · Therapeutic Advances in Childhood Leukemia Consortium (15) · Washington University School of Medicine (14) · Massachusetts General Hospital (13) · The First Affiliated Hospital of Soochow University (13)
United States (768) · China (153) · Germany (130) · Canada (127) · France (99) · Australia (95) · Italy (90) · Spain (83) · United Kingdom (69) · Belgium (58) · Netherlands (52) · Switzerland (48) · Austria (46) · Puerto Rico (46) · South Korea (45)
Elias Jabbour (9) · Amir Fathi, MD (6) · Sima Jeha, MD (6) · Hiroto Inaba, MD, PhD (5) · Tapan M Kadia (5) · Anjali Advani, MD (4) · Dieter Hoelzer, MD,PhD (4) · Elias Jabbour, MD (4) · Farhad Ravandi-Kashani, MD (4)
PMID 41671463, PMID 35622074, PMID 36184192, PMID 39121442, PMID 31171508, PMID 31375516, PMID 37267439, PMID 36815378, PMID 37890117, PMID 38295280, PMID 38446568, PMID 42085603, PMID 22965967, PMID 23007406, PMID 24383844, PMID 24970932, PMID 25527568, PMID 29618479, PMID 29702001, PMID 33242441, PMID 34162404, PMID 16105981, PMID 19144982, PMID 20154213, PMID 20625116, PMID 21719599, PMID 22442346, PMID 22493293, PMID 22627678, PMID 22649106, PMID 23024237, PMID 23233662, PMID 24344215, PMID 24816240, PMID 26590194, PMID 26888258, PMID 26913693, PMID 27507877, PMID 27561722, PMID 28273028, PMID 28419486, PMID 28751559, PMID 29148893, PMID 29284596, PMID 29720733, PMID 29926156, PMID 30337300, PMID 30523055, PMID 31188727, PMID 31601692
U10CA098543 (31), U10CA180886 (25), U10CA031946 (21), P30CA015704 (19), U10CA032102 (17), P30CA016672 (12), U10CA180821 (10), P30CA006973 (8), U01CA070095 (8), 2014 (7), 2023 (7), U10CA180888 (7), 2017 (6), P30CA033572 (6), U10CA180820 (6)